On December 24, several listed companies in Shanghai and Shenzhen issued announcements. The following is a summary of important announcements.
major events
Jiangsu Aidea Pharmaceutical Co.Ltd(688488) : it is proposed to transfer the technical secrets and patent rights of the new anti-tumor drug acc006 project of 100 million yuan
Jiangsu Aidea Pharmaceutical Co.Ltd(688488) (688488) announced in December 24th that the company and its subsidiary, awesome, signed the technology transfer contract with Lixin bio on the ACC006 project of the company’s anti-tumor drug research and development. The company and anassy transferred all the rights related to the technical secrets and patents of the underlying project to Li Xin biological, Lixin biological transferee project and paid the technology transfer fee of 100 million yuan (including tax). In addition, the company’s technical director and core technicians Li Wenquan and Hu xionglin applied for resignation from the company’s technical director and core technicians recently for personal reasons. The resignation of the above personnel will not affect the company’s production and operation and project R & D, and will not affect the company’s core technology and R & D work.
Beijing Aosaikang Pharmaceutical Co.Ltd(002755) : the subsidiary tegacyclin for injection passed the conformity evaluation of generic drugs
Beijing Aosaikang Pharmaceutical Co.Ltd(002755) (002755) announced on December 24 that the wholly-owned subsidiary Jiangsu Beijing Aosaikang Pharmaceutical Co.Ltd(002755) recently received the notice of approval for supplementary application of drugs for tegacyclin for injection approved and issued by the State Food and drug administration, approving the drug to pass the consistency evaluation of quality and efficacy of generic drugs. Clinically, the drug is mainly used for the treatment of infection caused by sensitive strains of specific bacteria in patients over 18 years old: complex intraperitoneal infection, complex skin and soft tissue infection, community-acquired bacterial pneumonia.
Haixin Foods Co.Ltd(002702) : executive voluntary salary reduction
Haixin Foods Co.Ltd(002702) (002702) it was announced on December 24 that the senior management of the company voluntarily proposed to reduce the salary in 2022. Based on the salary plan in 2021, the salary of Teng Yongyan, general manager, Zheng Shunhui, chief financial officer and Zhang Yingjuan, deputy general manager and Secretary of the board of directors were reduced by 52%, 19% and 11%.
Ruida Futures Co.Ltd(002961) : apply for withdrawal from the bankruptcy reorganization of wechat securities
Ruida Futures Co.Ltd(002961) (002961) announced on December 24 that according to the results of the company’s due diligence on wechat securities, after careful evaluation, the company decided not to participate in the public recruitment and selection of investors in the bankruptcy reorganization of wechat securities, and sent the communication letter on terminating the public recruitment and selection of investors in the bankruptcy reorganization of wechat securities to the administrator.
Luoxin Pharmaceuticals Group Stock Co.Ltd(002793) : pantoprazole sodium enteric coated tablets and cefprozil tablets passed the conformity evaluation of generic drugs
Luoxin Pharmaceuticals Group Stock Co.Ltd(002793) (002793) it was announced on December 24 that Shandong Luoxin, a subsidiary of the company, recently received the notice of approval of drug supplementary application for pantoprazole sodium enteric coated tablets and the notice of approval of drug supplementary application for cefprozil tablets approved and issued by the State Food and drug administration. After review, the above two drugs passed the consistency evaluation of generic drug quality and efficacy.
Zhejiang Zhongxin Fluoride Materials Co.Ltd(002915) : the company resumed work and production on December 24
Zhejiang Zhongxin Fluoride Materials Co.Ltd(002915) (002915) announced on December 24 that at present, the company has met the requirements of the implementation opinions on orderly resumption of work and production of industrial enterprises in Shangyu district. After the application of the company and the approval of the local government, the company began to resume work and production in an orderly manner on December 24.
Shanghai Yuyuan Tourist Mart (Group) Co.Ltd(600655) : it is proposed to invest 490 million yuan to participate in the establishment of private equity investment fund
Shanghai Yuyuan Tourist Mart (Group) Co.Ltd(600655) (600655) announced on December 24 that the company plans to establish Fosun (Hangzhou) Hanxing private equity investment fund partnership (limited partnership) jointly with Fosun high tech and Hangzhou Gongshu Industrial Fund Co., Ltd. The total subscribed capital contribution of the fund is 1 billion yuan, of which 490 million yuan is contributed by the company’s subordinate enterprises as limited partners. Fosun high tech is the controlling shareholder of the company. The actual controller of the company and Fosun high tech is Guo Guangchang. This transaction constitutes a related party transaction.
Super Telecom Co.Ltd(603322) : the controlling shareholder intends to transfer 4.59% of the company’s shares
Super Telecom Co.Ltd(603322) (603322) announced on December 24 that the controlling shareholder Liang Jianhua plans to transfer 4.59% of the company’s shares at the price of 8.85 yuan per share, with a total transfer price of 65.0333 million yuan, which is used to repay the stock pledge loan liabilities. After the transfer, the total proportion of shares held by Liang Jianhua and those acting in concert decreased from 35.21% to 30.62%.
Jiangsu Hengrui Medicine Co.Ltd(600276) : shr-1314 injection was approved for clinical trial
Jiangsu Hengrui Medicine Co.Ltd(600276) (600276) it was announced on December 24 that Suzhou shengdia biomedical Co., Ltd., a subsidiary of the company, received the notice of approval for clinical trial of shr-1314 injection approved and issued by the State Food and Drug Administration and will carry out clinical trial in the near future. The applied indication is adult active moderate to severe thyroid related ophthalmopathy.
Changzhou Qianhong Biopharma Co.Ltd(002550) : enoxaparin sodium injection passed the conformity evaluation of generic drugs
Changzhou Qianhong Biopharma Co.Ltd(002550) (002550) announced on December 24 that the company recently received the notice of approval for drug supplementary application for “enoxaparin sodium injection” approved and issued by the State Food and drug administration, approving the drug to pass the consistency evaluation of quality and efficacy of generic drugs.
Guizhou Salvage Pharmaceutical Co.Ltd(600227) : Acarbose Tablets obtained the drug registration certificate
Guizhou Salvage Pharmaceutical Co.Ltd(600227) (600227) announced on December 24 that on December 23, Guizhou Salvage Pharmaceutical Co.Ltd(600227) pharmaceutical, a wholly-owned subsidiary of the company, received the drug registration certificate approved and issued by the State Food and Drug Administration for the company’s drug Acarbose Tablets. Acarbose can effectively delay the hydrolysis of starch and other polysaccharides in the body, control postprandial blood glucose level and reduce the role of glycosylated hemoglobin, which is the largest selling variety of oral antidiabetic drugs in China.
Zhejiang Huangma Technology Co.Ltd(603181) : the company and its wholly-owned subsidiaries fully and orderly resume work and production
Zhejiang Huangma Technology Co.Ltd(603181) (603181) announced on December 24 that according to the implementation opinions on orderly resumption of work and production of industrial enterprises in Shangyu District issued by covid-19 epidemic prevention and control headquarters in Shangyu District, Shaoxing City on the afternoon of December 22, the company recently submitted a written application and resumption of work and production plan. After the territorial review and approval, the company and its wholly-owned subsidiary lvke’an company Real Madrid Shangyi company began to resume work and production comprehensively and orderly on December 24. As of the date of this announcement, the company’s inventory and production capacity can basically meet the requirements of the order delivery plan. The delivery period of some products has been appropriately adjusted, and the company’s undertaking of new orders has not been significantly affected. The covid-19 epidemic had no significant adverse impact on the company’s production and operation, and had little impact on the company’s overall performance in 2021.
Zhejiang Changhua Auto Parts Co.Ltd(605018) : the construction project of automobile stamping and welding parts (Wuhan) production base was officially put into operation
Zhejiang Changhua Auto Parts Co.Ltd(605018) (605018) announced on December 24 that the “automobile stamping and welding parts (Wuhan) production base construction project” is an investment project funded by the company’s initial public offering. It has officially entered the production stage, achieved mass production and supply, and completed the expected goal of putting into operation by the end of 2021.
refinancing
Shanghai Rural Commercial Bank Co.Ltd(601825) : the issuance of tier 2 capital bonds not exceeding 10 billion yuan has obtained the administrative license of the central bank
Shanghai Rural Commercial Bank Co.Ltd(601825) (601825) announced on December 24 that the company recently received the decision on granting administrative license from the people’s Bank of China and agreed to issue tier 2 capital bonds of no more than 10 billion yuan in the national inter-bank bond market.
sign the contract
Quantumctek Co.Ltd(688027) : signed a 40.49 million yuan quantum equipment and system procurement contract with Digital China Group Co.Ltd(000034)
Quantumctek Co.Ltd(688027) (688027) announced on December 24 that Beijing Quantumctek Co.Ltd(688027) Information Technology Co., Ltd., a wholly-owned subsidiary of the company, and Digital China Group Co.Ltd(000034) signed a sales contract for the procurement of quantum equipment and systems for the national wide area quantum secure communication backbone network construction project (Beijing to Harbin), with a contract amount of 40.4925 million yuan (including tax).
winning project
Tengda Construction Group Co.Ltd(600512) : won the bid for the 73.5059 million yuan new plant project
Tengda Construction Group Co.Ltd(600512) (600512) announced on December 24 that recently, the company received the letter of acceptance of construction project issued by Jiushan Village joint stock economic cooperative, Yucheng street, Yuhuan City, and determined that the company was the bid winner of the project of “new plant project in Jiushan small and micro enterprise park, Yucheng Street, Yuhuan City, Zhejiang Province”, with a bid winning amount of 73.5059 million yuan.
increase and decrease
Shanghai Ceo Environmental Protection Technology Co.Ltd(688335) : some actual controllers, directors, supervisors and senior management plan to increase their holdings of the company’s shares by RMB 2.9 million-5.8 million
Shanghai Ceo Environmental Protection Technology Co.Ltd(688335) (688335) announced on December 24 that some actual controllers, directors, supervisors and senior managers of the company plan to increase their holdings of the company’s shares by means allowed by the system of Shanghai Stock Exchange (including but not limited to call auction, continuous bidding and block trading) within 6 months from December 27, 2021, with a total increase of no less than 2.9 million yuan and no more than 5.8 million yuan.
Hangzhou Haoyue Personal Care Co.Ltd(605009) : the shareholder Wenzhou Outai plans to reduce its holding of no more than 3% shares
Hangzhou Haoyue Personal Care Co.Ltd(605009) (605009) announced on December 24 that the shareholder Wenzhou Outai plans to reduce its holdings of no more than 4795100 shares through block trading, that is, no more than 3% of the total share capital of the company.
Jiangsu Feiliks International Logistics Inc(300240) : the controlling shareholder plans to reduce the total shares of no more than 5%, and the president plans to increase the shares of the company
Jiangsu Feiliks International Logistics Inc(300240) (300240) announced on December 24 that the total reduction of the three controlling shareholders of Feida investment, Yatong auto repair and Jilida investment shall not exceed 18396700 shares, that is, the total reduction shall not reach or exceed 5% of the total share capital of the company. In addition, Geng Hao, director and President of the company, plans to increase his holdings of the company’s shares within six months from the date of disclosure of the announcement. The price range is not set in the increase plan, and the number of additional shares is no less than 2.8 million shares and no more than 5.6 million shares.
Inner Mongolia Eerduosi Resources Co.Ltd(600295) : the controlling shareholder and its persons acting in concert intend to increase their holdings of B-Shares of the company by US $10 million to US $10.1 million
Inner Mongolia Eerduosi Resources Co.Ltd(600295) (600295) announced on December 24 that the controlling shareholder of the company, Inner Mongolia Inner Mongolia Eerduosi Resources Co.Ltd(600295) Cashmere Group Co., Ltd., acting in concert, Hong Kong company, increased its B-Shares by 631500 shares on December 24, accounting for 0.0442% of the total share capital, and the transaction capital was us $1256600; The controlling shareholders and their persons acting in concert intend to increase their holdings of B-Shares of the company by US $10 million to US $10.1 million within 12 months, with an increase price of US $1.2 to US $2.2 per share.
Oke Precision Cutting Tools Co.Ltd(688308) : vertical and horizontal financing and its persons acting in concert intend to reduce their holdings of no more than 2% shares
Oke Precision Cutting Tools Co.Ltd(688308) (688308) announced on December 24 that the vertical and horizontal financing of the company’s shareholders with a total shareholding of 5% and the person acting in concert, Yueke Nanyue, plans to reduce their total holdings of the company’s shares by means of centralized bidding, which is no more than 2 million shares, that is, no more than 2% of the total shares of the company.
Hubei Feilihua Quartz Glass Co.Ltd(300395) : the actual controller and others plan to reduce their total holdings of no more than 1.24% shares
Hubei Feilihua Quartz Glass Co.Ltd(300395) (300395) announced on December 24 that the actual controllers Deng Jiagui and Wu Xuemin, the directors Shang Chunli, Wu Jian and Lu Xiaohui, the supervisor Li Zairong and the senior management Xu Yan plan to reduce their total holdings of no more than 1.243% of the company’s shares.
Sinomach Precision Industry Co.Ltd(002046) : Great Wall Fund plans to reduce its holdings of no more than 2.51% shares
Sinomach Precision Industry Co.Ltd(002046) (002046) announced on December 24 that Great Wall Fund, a shareholder with a shareholding of 7.51%, plans to reduce its holdings of no more than 13.14 million shares (accounting for 2.51% of the total share capital of the company) by means of centralized bidding in the secondary market and block trading.
Sino Medical Sciences Technology Inc(688108) : several shareholders intend to reduce their shares by no more than 17.97%
Sino Medical Sciences Technology Inc(688108) (688108) announced on December 24 that great noble Investment Limited, a shareholder holding 10.8267%, intends to reduce its holdings of no more than 6% of the company’s shares. Denlux microport investment Inc., a shareholder with a total shareholding of 6.56%. And its concerted action denlux capital Inc. It is proposed to reduce not more than 6% of the company’s shares. CSF stent limited, a shareholder holding 5.97%, intends to reduce its holdings of no more than 5.97% of the company’s shares.
Shanghai Qifan Cable Co.Ltd(605222) : some directors, supervisors and senior executives plan to increase their shares by 2 million yuan to 2.5 million yuan
Shanghai Qifan Cable Co.Ltd(605222) (605222) announced on December 24 that some directors, supervisors and senior managers plan to increase their holdings by 2-2.5 million yuan within one month at a price of no more than 30 yuan / share.
